Northwest Biotherapeutics (OTCMKTS:NWBO) Posts Quarterly Earnings Results

Northwest Biotherapeutics (OTCMKTS:NWBO) posted its quarterly earnings results on Friday. The biotechnology company reported ($0.02) earnings per share (EPS) for the quarter, Zacks reports.

Northwest Biotherapeutics Stock Down 5.2%

Shares of NWBO stock traded down $0.01 on Friday, hitting $0.16. The stock had a trading volume of 4,713,982 shares, compared to its average volume of 3,421,022. The business has a 50 day moving average price of $0.16 and a 200 day moving average price of $0.20. The company has a market cap of $285.45 million, a PE ratio of -0.01 and a beta of -0.59. Northwest Biotherapeutics has a one year low of $0.14 and a one year high of $0.34.

Northwest Biotherapeutics Company Profile

Northwest Biotherapeutics is a biotechnology company developing immunotherapies for cancer, with a focus on treatments made from a patient’s own immune cells. Its platform uses dendritic cells, which can help the immune system recognize and respond to cancer. The company’s lead product candidate, DCVax-L, is a personalized dendritic-cell therapy being developed for glioblastoma, an aggressive form of brain cancer. Northwest Biotherapeutics has also developed DCVax-Direct, an investigational therapy designed to be injected into tumors.